Form 4: Acrivon Therapeutics Insider Sells Shares

Mary Miller, Chief Legal Officer of Acrivon Therapeutics, Inc., reported a disposition of 49,830 shares of common stock on May 18, 2026.

Summary

• Mary Miller, Chief Legal Officer at Acrivon Therapeutics, Inc., has reported a transaction involving company stock.
• On May 18, 2026, Miller disposed of 49,830 shares of common stock.
• The transaction code indicates a disposition, and the price is listed as $0, suggesting a non-sale transfer or a grant-related event.
• Following this transaction, Miller beneficially owns 82,767 shares of common stock.
• The filing also details that 49,830 shares represent restricted stock units (RSUs), with vesting schedules outlined for November 18, 2026, and subsequent quarterly installments, contingent on continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. While an insider disposition can sometimes signal caution, the $0 price and the nature of RSUs suggest it's likely part of a compensation plan rather than a direct sale of stock for profit.

Positives

• Mary Miller continues to hold a significant number of shares (82,767) after the reported transaction, indicating continued investment in the company.
• The reported transaction of RSUs with a vesting schedule suggests a long-term incentive structure for management, aligning their interests with the company's performance over time.

Negatives

• The disposition of 49,830 shares by a key executive could be perceived negatively by the market, although the $0 price suggests it may not be a direct sale for cash.

Risks

• The vesting of RSUs is contingent on the Reporting Person's continuous service, implying a risk of forfeiture if employment is terminated before vesting dates.
• The nature of the transaction at $0 price needs further clarification to fully assess its implications, as it could represent a grant, forfeiture, or other non-standard event.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports a change in beneficial ownership.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The reporting of Restricted Stock Units (RSUs) and their vesting schedules is a common compensation practice in the biotechnology and pharmaceutical sectors, aiming to retain key talent.

Stakeholder Impact

• Shareholders: The disposition of shares by an executive may be monitored, but the $0 price and RSU nature suggest limited immediate impact on share price or perceived value.
• Employees: The RSU vesting schedule reinforces the company's strategy to incentivize and retain key personnel through performance-based equity.
• Management: The transaction is part of Mary Miller's compensation and equity ownership structure within Acrivon Therapeutics.

Next Steps

• Continued vesting of RSUs subject to continuous service through each vesting date.
• Monitoring of future insider transactions for further insights into management's confidence in the company.

Key Dates

Keywords

Acrivon Therapeutics, ACRV, Form 4, Insider Transaction, Stock Disposition, Restricted Stock Units, RSU Vesting, Mary Miller, Chief Legal Officer